Polyneuron Pharmaceuticals Overview

  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1.29M
Latest Deal Amount
  • Investors
  • 15

Polyneuron Pharmaceuticals General Information

Description

Developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

Contact Information

Website
www.polyneuron.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • C/O ErfindungsVerwertung AG
  • Hochbergerstrasse 60c
  • 4057 Basel
  • Switzerland

Polyneuron Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Polyneuron Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 14-Apr-2021 $1.29M 000.00 Completed Generating Revenue
7. Later Stage VC (Series A) 28-Aug-2020 000.00 000.00 Completed Pre-Clinical Trials
6. Seed Round 14-May-2018 00.000 00.000 00.000 Completed Pre-Clinical Trials
5. Accelerator/Incubator 18-Sep-2017 000.00 00000 Completed Pre-Clinical Trials
4. Grant 31-Aug-2017 00000 00000 Completed Pre-Clinical Trials
3. Grant 05-May-2016 00000 00000 Completed Pre-Clinical Trials
2. Accelerator/Incubator 02-Jun-2015 $150K $150K Completed Pre-Clinical Trials
1. Grant 01-Oct-2013 $32.5K Completed Startup
To view Polyneuron Pharmaceuticals’s complete valuation and funding history, request access »

Polyneuron Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series Seed 000,000 000.00 000.00 00 000.00 00.000
To view Polyneuron Pharmaceuticals’s complete cap table history, request access »

Polyneuron Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The compa
Drug Discovery
Basel, Switzerland
16 As of 2021
000.00
0000000000 000.00

0000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
000000000000000
Beijing, China
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

00 00000

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
000000000000000
Cambridge, MA
00 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Polyneuron Pharmaceuticals Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Jacobio Pharmaceuticals Formerly VC-backed Beijing, China 000 00000 00000000 00000
00 000000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
0000000000 Formerly VC-backed Goteborg, Sweden 0 00.000 00000000 00.000
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000 Venture Capital-Backed Diepenbeek, Belgium 0 000.00 000000 - 000 000.00
You’re viewing 5 of 42 competitors. Get the full list »

Polyneuron Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
Ruben Herrendorff Ph.D Co-Founder, Chief Executive Officer & Board Member
Pascal Hänggi Ph.D Co-Founder & Chief Scientific Officer
Aled Williams Chief Business Officer
Beat Ernst Ph.D Co-Founder, Board Member & Scientific Advisor
Andreas Steck Co-Founder & Scientific Advisor
You’re viewing 5 of 7 executive team members. Get the full list »

Polyneuron Pharmaceuticals Board Members (9)

Name Representing Role Since
Bernardus Machielse Self Chairman of the Board 000 0000
Bibhash Mukhopadhyay Ph.D Self Board Member 000 0000
David Mott New Enterprise Associates Board Member 000 0000
Emil Bujak Ph.D Self Board Member 000 0000
Graziano Seghezzi Sofinnova Partners Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Polyneuron Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Polyneuron Pharmaceuticals Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innosuisse Government Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Sofinnova Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial